Impact of Abdominal Incompetence on Urinary Incontinence After Prostatectomy (PROSTABDO) (PROSTABDO)
Impact de l'incompétence Abdominale Sur l'Icontinence Urinaire Post Prostatectomie
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Emilie CERUTTI
- Phone Number: 0381218876
- Email: ecerutti@chu-besancon.fr
Study Locations
-
-
-
Besançon, France, 25000
- Recruiting
- University Hospital of Besancon
-
Contact:
- Emilie CERUTTI
- Phone Number: 0381218876
- Email: ecerutti@chu-besancon.fr
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- male with prostate cancer going to have a robotic-assisted laparoscopic radical prostatectomy
Exclusion Criteria:
- neurological patology with bladder impact (SCI, parkinson disease, multiple sclerosis....)
- urinary incontinence before surgery
- surgery for abdominal wallhernia
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Screening
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Other: patient before Robotic-assisted Radical Prostatectomy
evaluation of deep abdominal wall before surgery : cough test + ulstrasonography of transversus abdominis
|
: cough test (L guillarme) + ulstrasonography of transversus abdominis
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
amount of incontinence after surgery (1 year)
Time Frame: 1 year
|
mesured with pad test on 3 days
|
1 year
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
amount of incontinence after 3 month
Time Frame: 3 month
|
mesured with pad test on 3 days
|
3 month
|
|
amount of incontinence after 6 month
Time Frame: 6 month
|
mesured with pad test on 3 days
|
6 month
|
|
quality of life after 3 month
Time Frame: 3 month
|
Short-Form (SF-36) Health Survey
|
3 month
|
|
quality of life after6 month
Time Frame: 6 month
|
Short-Form (SF-36) Health Survey
|
6 month
|
|
quality of life after 12 month
Time Frame: 12 month
|
Short-Form (SF-36) Health Survey
|
12 month
|
|
quality of incontinence after 12 month
Time Frame: 12 month
|
mesured with urinary symptom profil score
|
12 month
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Emilie CERUTTI, University Hospital of Besancon
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2021/664
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.